Dublin, Feb. 20, 2024 (GLOBE NEWSWIRE) -- The "Global Incretin Based Drugs Market (2023 Edition): Analysis By Drug Type (Glucagon-like Peptide-1 Receptor Agonists, Dipeptidyl Peptidase-4 Inhibitors), Route of Administration, By Indication, By Region, By Country: Market Insights and Forecast (2019-2029)" report has been added to ResearchAndMarkets.com's offering.
This report meticulously segments the market by drug type, including Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors, and investigates potential by route of administration, with focus on oral and injectable drugs, further enriched by insights into indications such as Diabetes and Obesity.
Anticipated Market Expansion
Forecasts suggest that the Global Incretin Based Drugs market is set to flourish from 2024 through 2029, with an impressive CAGR of 6.8%. By 2029, the market valuation is projected to reach USD 64.28 billion, an escalation from the USD 40.72 billion recorded in 2022. This acceleration is partly driven by increased prevalence of type 2 diabetes, spotlighting the critical need for advanced therapeutic options.
Regional and Country-Wise Insights
An in-depth review has been conducted across various regions including the Americas, Europe, Asia-Pacific (APAC), and the Middle East & Africa (MEA). Country-specific analysis includes a deep dive into ten key markets: the United States, Canada, Germany, the United Kingdom, France, Italy, Spain, China, Japan, and India, presenting a nuanced understanding of incretin-based drug dynamics on a global scale.
Report Highlights and Competitive Landscape
- The report examines market trends, key drivers, and challenging dynamics.
- Comprehensive analysis using SWOT and Porter’s Five Forces models.
- Market attractiveness segmented by region, drug type, and indication.
- Critical examination of competitive strategies and industry developments.
- Analysis includes leading market players like Eli Lilly and Company, Boehringer Ingelheim, Novo Nordisk, and AstraZeneca PLC among others.
Key Market Benefits
Incretin based drugs are renowned for their ability to manage hyperglycemia without the associated risks of hypoglycemia or weight gain. The diversification of the market, including generic availability and advanced formulations, is set to meet growing patient and practitioner needs.
Methodical Research Focused on Comprehensive Growth
The report lays out an integral strategy for stakeholders by providing a throughline from past trends to future possibilities. This document stands as a quintessential resource for industry players looking to strategize, invest, and align with the anticipated growth in the incretin based drugs market.
The evolving pharmaceutical landscape underlines the necessity for targeted therapeutics in the face of rising lifestyle diseases. As the market surges forward, this report is positioned as an essential tool for enthusiasts and professionals to grasp upcoming opportunities and turn insights into action.
Understanding The Incretin Based Drugs Market Trajectory
The incretin based drugs market is witnessing a transformative phase characterized by innovation and an increased emphasis on patient-centric solutions. The analysis enclosed within this report offers a clear perspective on the factors propelling the market forward, with particular attention on the differential efficacy and tolerability profiles of incretin-based therapies.
The insights garnered here are instrumental for healthcare providers, pharmaceutical companies, investors, and policy-makers to navigate the complexities of the market while aligning with the overarching themes of industry progress and patient care advancements.
Scope of the Report:
- Global Incretin Based Drugs Market: Historic and Forecast (2018-2028)
- Global Obesity Statistics 2022, in Millions
- Pipeline Analysis of Incretin based drugs
- Countries with the highest prevalence of diabetes worldwide in 2021
- Estimated number of individuals with Diabetes Worldwide, in thousands (2000-2014E)
- Global Incretin-Based Drugs Market: Dashboard
- Global Incretin Based Drugs Market: Market Value Assessment, 2018-2028 (USD Billion)
- Impact of COVID-19 on Global Incretin Based Drugs Market
- Global Incretin-Based Drugs Market Segmentation: By Drug Type
- Global Incretin-Based Drugs Market, By Drug Type Overview
- Global Incretin Based Drugs Market Size, By Glucagon-like Peptide-1 Receptor Agonists, By Value, 2018H-2028F (USD Billion & CAGR)
- Global Incretin Based Drugs Market Size, By Dipeptidyl Peptidase-4 Inhibitors, By Value, 2018H-2028F (USD Billion & CAGR)
- Global Incretin-Based Drugs Market, By Route of Administration Overview
- Global Incretin-Based Drugs Market Size, By Oral, By Value, 2018H-2028F (USD Billion & CAGR)
- Global Incretin-Based Drugs Market Size, By Injectables, By Value, 2018H-2028F (USD Billion & CAGR)
- Global Incretin Based Drugs Market, By Indication Overview
- Global Incretin Based Drugs Market Size, By Diabetes By Value, 2018H-2028F (USD Billion & CAGR)
- Global Incretin Based Drugs Market Size, By Obesity, By Value, 2018H-2028F (USD Billion & CAGR)
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 230 |
| Forecast Period | 2024 - 2029 |
| Estimated Market Value (USD) in 2024 | $46.28 Billion |
| Forecasted Market Value (USD) by 2029 | $64.28 Billion |
| Compound Annual Growth Rate | 6.7% |
| Regions Covered | Global |
Competitive Positioning
- Companies' Product Positioning
- Market Position Matrix
- Market Share Analysis of Incretin-Based Drugs Market
Company Profiles
- Eli Lilly and Company
- Boehringer Ingelheim
- Novo Nordisk
- AstraZeneca PLC
- Merck & Co., Inc.
- Pfizer
- Novartis AG
- Takeda Pharmaceuticals
- Bristol Myers Squibb
- Structure Therapeutics
For more information about this report visit https://www.researchandmarkets.com/r/gha1av
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
